Switzerland· 69889003
Yorvipath 420 μg/1.4 ml, Injektionslösung im Fertigpen
A palopegteriparatide product containing palopegteriparatidum, registered in Switzerland by Ascendis Pharma Switzerland GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Palopegteriparatide is registered in 11 of 19 countries.
Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Palopegteriparatide · ATC H05AA05
11 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- palopegteriparatidum
- Manufacturer
- Ascendis Pharma Switzerland GmbH
- Country
- Switzerland (CH)
- ATC code
- H05AA05
- ATC class
- Palopegteriparatide
- Defined daily dose
- 33 mcg, P
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- BelgiumYorvipath 168 µg/0.56 mlAscendis Pharma Bone Diseases
- SpainYORVIPATH 168 MICROGRAMOS/0,56 ML SOLUCION INYECTABLE EN PLUMA PRECARGADAAscendis Pharma Bone Diseases A/S
- PolandYorvipathAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- United StatesYorvipathAscendis Pharma, Endocrinology, Inc.
- United KingdomYorvipath 168micrograms/0.56ml solution for injection pre-filled pensAscendis Pharma UK Ltd
- NetherlandsYorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde penAscendis Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9b0d862-adc3-4c96-b8c8-ef9702fd1f16 GET /v1/drugs/e9b0d862-adc3-4c96-b8c8-ef9702fd1f16?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.